JP2022507265A5 - - Google Patents
Info
- Publication number
- JP2022507265A5 JP2022507265A5 JP2021525753A JP2021525753A JP2022507265A5 JP 2022507265 A5 JP2022507265 A5 JP 2022507265A5 JP 2021525753 A JP2021525753 A JP 2021525753A JP 2021525753 A JP2021525753 A JP 2021525753A JP 2022507265 A5 JP2022507265 A5 JP 2022507265A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- composition
- compound
- alkyl
- electron
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862767424P | 2018-11-14 | 2018-11-14 | |
| US62/767,424 | 2018-11-14 | ||
| PCT/US2019/061474 WO2020102529A1 (en) | 2018-11-14 | 2019-11-14 | Electrophiles and electrophile pro-drugs as rad51 inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022507265A JP2022507265A (ja) | 2022-01-18 |
| JP2022507265A5 true JP2022507265A5 (cg-RX-API-DMAC10.html) | 2022-11-18 |
| JP7656922B2 JP7656922B2 (ja) | 2025-04-04 |
Family
ID=70732197
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021525753A Active JP7656922B2 (ja) | 2018-11-14 | 2019-11-14 | Rad51阻害薬としての求電子剤および求電子剤プロドラッグ |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12390435B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3880188A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP7656922B2 (cg-RX-API-DMAC10.html) |
| CN (1) | CN112996493A (cg-RX-API-DMAC10.html) |
| CA (1) | CA3114406A1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2020102529A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12390435B2 (en) | 2018-11-14 | 2025-08-19 | University of Pittsburgh—of the Commonwealth System of Higher Education | Electrophiles and electrophile pro-drugs as RAD51 inhibitors |
| WO2023025263A1 (en) * | 2021-08-25 | 2023-03-02 | Ensem Therapeutics Holding (Singapore) Pte. Ltd. | Systems and methods for post-translational modification-inspired drug design and screening |
| KR20230102353A (ko) * | 2021-12-30 | 2023-07-07 | 주식회사 대웅제약 | 삼중음성유방암의 예방 또는 치료용 약학적 조성물 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005110396A2 (en) | 2004-04-28 | 2005-11-24 | Uab Research Foundation | Nitrated lipids and methods of making and using thereof |
| EP2679224A1 (en) | 2007-08-01 | 2014-01-01 | University of Pittsburgh of the Commonwealth System of Higher Education | Nitro oleic acid modulation of type II diabetes |
| DK2280928T3 (en) * | 2008-05-01 | 2018-11-05 | Complexa Inc | Vinyl-substituted fatty acids |
| CN102099024B (zh) * | 2008-06-19 | 2015-11-25 | 犹他大学研究基金会 | 硝化脂质在毒性医疗疗法的副作用的治疗上的用途 |
| CA2769624C (en) | 2009-07-31 | 2018-09-11 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Electrophilic fatty acid derivatives as anti-inflammatory agents |
| WO2011041639A2 (en) * | 2009-10-02 | 2011-04-07 | Miller Raymond A | Heteroatom containing substituted fatty acids |
| WO2013116753A1 (en) | 2012-02-03 | 2013-08-08 | University Of Pittsburgh-Of The Commonwelth System Of Higher Education | Fatty acids as anti-inflammatory agents |
| EP3283061A4 (en) | 2015-04-14 | 2019-04-17 | Atossa Genetics Inc. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BREAST DISEASES AND ORGANISM-RELATED ILLNESSES |
| US10751310B2 (en) | 2016-03-04 | 2020-08-25 | University of Pittsburgh—of the Commonwealth System of Higher Education | Prevention, treatment and reversal of disease using therapeutically effective amounts of dicarboxylic acid compounds |
| CA3039376A1 (en) | 2016-10-05 | 2018-04-12 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Reversibly protected thiolated electrophilic fatty acids as prodrugs |
| WO2018067709A1 (en) | 2016-10-05 | 2018-04-12 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Novel reversible nitroxide derivatives of nitroalkenes that mediate nitrosating and alkylating reactions |
| US12390435B2 (en) | 2018-11-14 | 2025-08-19 | University of Pittsburgh—of the Commonwealth System of Higher Education | Electrophiles and electrophile pro-drugs as RAD51 inhibitors |
-
2019
- 2019-11-14 US US17/290,963 patent/US12390435B2/en active Active
- 2019-11-14 CA CA3114406A patent/CA3114406A1/en active Pending
- 2019-11-14 EP EP19885442.4A patent/EP3880188A4/en active Pending
- 2019-11-14 JP JP2021525753A patent/JP7656922B2/ja active Active
- 2019-11-14 CN CN201980074600.3A patent/CN112996493A/zh active Pending
- 2019-11-14 WO PCT/US2019/061474 patent/WO2020102529A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Vis et al. | Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways | |
| CN117919235A (zh) | 一种萘酰胺化合物治疗kras突变相关疾病的用途 | |
| Mostaghel et al. | Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants | |
| Hoy | Abiraterone acetate: a review of its use in patients with metastatic castration-resistant prostate cancer | |
| Devulapally et al. | Formulation of anti-miR-21 and 4-hydroxytamoxifen co-loaded biodegradable polymer nanoparticles and their antiproliferative effect on breast cancer cells | |
| US20220000824A1 (en) | Treatment of pulmonary arterial hypertension using therapeutically effective oral doses of 10-nitro-9(e)-octadec-9-enoic acid | |
| EP3791897A1 (en) | Hsp90 inhibitor drug conjugates | |
| Hassan et al. | MicroRNA-122 mimic/microRNA-221 inhibitor combination as a novel therapeutic tool against hepatocellular carcinoma | |
| CN114432318A (zh) | 用于起因于剪接异常的遗传性疾病的药物组合物及治疗方法 | |
| Blazek et al. | Novel therapies on the horizon of hypertension management | |
| JP2013531038A (ja) | 癌の治療のための低酸素活性化プロドラッグおよび血管新生阻害剤の投与方法 | |
| JP7197370B2 (ja) | がんの予防および/または治療のための化合物、組成物および方法 | |
| JP2020516646A (ja) | 前立腺癌の併用療法 | |
| JP2016515630A5 (cg-RX-API-DMAC10.html) | ||
| US20230414635A1 (en) | Concomitant administration of glucocorticoid receptor modulators and cyp3a inhibitors | |
| US20200108089A1 (en) | Gemcitabine Derivatives for Cancer Therapy | |
| US20250248999A1 (en) | Bavdegalutamide and combinations thereof for use in treating prostate cancer | |
| JP6918020B2 (ja) | [8−(フェニルスルホニル)−3,8−ジアザビシクロ[3.2.1]オクタ−3−イル](1h−1,2,3−トリアゾール−4−イル)メタノン | |
| EP3861119A1 (en) | Splicing-dependent transcriptional gene silencing or activation | |
| CN109125313B (zh) | 一种复合制剂及其在制备肿瘤治疗药物中的用途 | |
| Tsang et al. | U1 adaptors suppress the KRAS-MYC oncogenic axis in human pancreatic cancer xenografts | |
| WO2012109527A2 (en) | Class of hdac inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury | |
| WO2006003013B1 (de) | NEUE 2-SUBSTITUIERTE ESTRA-1,3,5(10)-TRIEN-17-ONE ALS INHIBITOREN DER 17β-HYDROXYSTEROIDDEHYDROGENASE TYP 1 | |
| Salem et al. | Abiraterone acetate, a novel adrenal inhibitor in metastatic castration-resistant prostate cancer | |
| WO2014159774A1 (en) | Custirsen treatment with reduced toxicity |